WhiteLab Genomics
Paris-based company using AI to design gene delivery vehicles and other components of genomic medicines.
- Industry
- biotechnology, AI platform for genomic medicines
- Location
- Paris, France
About
WhiteLab Genomics designs the components of genomic medicines with AI: the vehicles that carry genetic material into cells and the elements that control where and when a therapeutic gene is expressed. European Biotechnology reports that the company is building a portfolio of validated assets it can own and license.
David Del Bourgo is co-founder and CEO, according to European Biotechnology.
Funding history
| Round | Date | Amount | Lead |
|---|---|---|---|
| Series B 2026 | 2026-10-06 | $26M | AVP |
Investors
- AVP lead
- Yaday Health participant
- Blast Club participant
- Omnes Capital participant
- Debiopharm Innovation Fund participant
Sources
Last verified:
- https://european-biotechnology.com/latest-news/whitelab-secures-26m-to-expand-ai-designed-gene-delivery-assets/
Type: reputable publication. Accessed 2026-10-06.
European Biotechnology article dated 2026-10-06. Reports $26 million (€23 million) in Series B financing led by AVP, with new investors Yaday Health and Blast Club and existing shareholders Omnes Capital and Debiopharm Innovation Fund. - https://www.finsmes.com/2026/10/whitelab-genomics-raises-26m-in-series-b-funding.html
Type: reputable publication. Accessed 2026-10-06.
FinSMEs article dated 2026-10-06. Source of the Paris, France location. Its body says $26M, while its headline says $25M. It names the existing investors as Omnes and Debiopharm.